GlaxoSmithKline's combination benign prostatic hyperplasia (BPH) drug Combodart (dutasteride 0.5mg/tamsulosin hydrochloride 0.4mg) has been launched in the UK, its first market.
The once-daily pill combines GSK's 5-alpha reductase inhibitor Avodart (dutasteride), which was launched in the UK in 2003, with the...